Cognitive Function and Quality of Life in Hypertension — A Community Based Study

Battersby, Clare; Hartley, K.; Fletcher, Anne; Markowe, Hugh L.J.; Brown, Richard M.; Styles, W M; Sapper, H.; Bulpitt, C

doi:10.1042/cs076016p

Cited by 47 publications

(63 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies have shown no difference in symptoms between hypertensive and non-hypertensive patients, 24,25 whereas others have reported more symptoms and impaired well-being compared with normotensive control patients. [2][3][4][5][6][7] The findings of the present study regarding the differences in HQL between the hypertensive patients and the normal controls is consistent with previous populationbased studies. 2,[26][27][28][29][30] These studies, however, did not simultaneously measure disease-specific symptoms and HQL.…”

Section: Discussionsupporting

confidence: 91%

“…2,[17][18][19][20][21][22][23] Some of the same frequently reported symptoms were also associated with significantly more distress among the hypertensive patients, such as breathing problems, dizziness, flushing/constipation, increased urination, and weariness. These symptoms may influence the SF-36 domains such as general health, physical functioning, vitality, and the physical summary score.…”

Section: Discussionmentioning

confidence: 99%

“…1 Although hypertension is thought to be asymptomatic, cognitive changes, mood alterations, and general symptoms such as dizziness and head-ache attributable to hypertension have been described. [2][3][4][5][6][7] Some symptoms are unique to antihypertensive medications, but overlap with symptoms described or attributed to the disease of hypertension as well as the general symptoms seen in a primary care population.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls

2001

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls

2001

View full text Add to dashboard Cite

“…4 Thus, quality of life on a population level is operationally defined in part by global self-health appraisals like those shown to be sensitive to hypertension labelling. 8,9,[11][12][13]25 If blood pressure screening and concomitant hypertensive labelling reduce SRH, then success in some elements of public health promotion (blood pressure screening and hypertension control) may erode progress in others (quality of life), particularly for those who are mislabelled.…”

Section: Introductionmentioning

confidence: 99%

Hypertension labelling was associated with poorer self-rated health in the Third US National Health and Nutrition Examination Survey

Barger

Muldoon

2005

J Hum Hypertens

View full text Add to dashboard Cite

Individuals labelled as having hypertension tend to report poor self-rated health (SRH), but it is unclear whether this association is independent of actual hypertension, socioeconomic status and adiposity, and extends across racial and ethnic groups. In a cross-sectional study we compared hypertensive and normotensive individuals (N ¼ 19 057) who varied in whether they had ever been labelled hypertensive. Blood pressure was measured in participants' homes and mobile examination centres in the United States as part of the Third National Health and Nutrition Examination Survey, 1988Survey, -1994. The main outcome measure was global SRH. Hypertensive labelling was associated with poorer SRH and was independent of established SRH predictors, antihypertensive medication use, body mass index, and hypertension status (adjusted odds ratio (OR) ¼ 1.79, 95% confidence interval (CI), 1.61-1.99). Hypertension was also associated with poorer SRH (OR ¼ 1.26; 95% CI 1.09-1.46) but this association was eliminated by adjustment for hypertensive labelling (OR 1.06; 95% CI 0.92-1.22). These effects were consistent across non-Hispanic white, non-Hispanic black, and Hispanic subgroups. Individuals labelled hypertensive are more likely to have lower SRH and this labelling effect predominates over that of actual hypertension. Public health efforts to increase the number of individuals screened for high blood pressure may successfully detect the presence of hypertension but may also reduce health-related quality of life as measured by global SRH.

show abstract

“…14 Hypertension is usually described as asymptomatic in the absence of significant target organ damage and concomitant disease, although cognitive changes, mood alterations and general symptoms, such as dizziness and headache, have been described. [15][16][17][18][19] Some symptoms are unique to the effects of antihypertensive drugs, whereas others overlap with symptoms described as or attributed to the hypertensive disease itself or are inseparable from those observed throughout the primary care population. 14 The ultimate goal of antihypertensive treatment is the reduction of cardiovascular mortality and morbidity.…”

Section: Discussionmentioning

confidence: 99%

Antihypertensive treatment using an angiotensin receptor blocker and a thiazide diuretic improves patients’ quality of life: The Saga Challenge Antihypertensive Study (S-CATS)

Kamura

Inoue

Kuroki³

et al. 2011

Hypertens Res

View full text Add to dashboard Cite

The aim of the Saga Challenge Antihypertensive Study (S-CATS), a single-arm, prospective and multi-center trial, was to evaluate the effectiveness of combined antihypertensive treatment with losartan and hydrochlorothiazide (HCTZ). Enrolled in the study were a total of 161 patients with hypertension, who in spite of treatment with an angiotensin receptor blocker (ARB) alone or an ARB and calcium channel blocker (CCB), had not been able to reach blood pressure control goals set by the Japanese Society of Hypertension Guidelines (JSH 2004). The ARBs were replaced with a combination pill containing losartan (50 mg) and HCTZ (12.5 mg), and this treatment was continued for 3 months. This change in therapy resulted in significant decreases in systolic (158 ± 14 to 137 ± 15 mm Hg, Po0.001) and diastolic (85 ± 11 to 76 ± 10 mm Hg, Po0.001) blood pressure and heart rate (73±3 to 72±3) during the study. The patients' quality of life (QOL) score, the EuroQol 5 dimensions (EQ-5D) and the visual analog scale (VAS) (n¼96; 70.0 (68.8-80.0) to 80.0 (70.0-90.0), Po0.01) all improved significantly. Another QOL score, the hypertension symptom score (HSS), which we originally developed for the S-CATS trial, decreased significantly (n¼93; 4.0 (1.0-9.0) to 2.0 (1.0-8.0), Po0.05). The Pittsburgh sleep quality index (PSQI), which is a psychometric assessment of subjective sleep quality, also decreased significantly (n¼45; 4.0 (2.0-7.0) to 3.0 (2.0-5.0), Po0.05). There was a significant correlation between a change in HSS (baseline value À3-months value) and a decrease in systolic blood pressure (n¼93; R¼0.241, Po0.05). These results suggest that an anti-hypertensive treatment combined with an ARB and a thiazide diuretic may improve patients' QOL, including sleep quality.

show abstract

Cognitive Function and Quality of Life in Hypertension — A Community Based Study

Cited by 47 publications

References 0 publications

Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls

Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls

Hypertension labelling was associated with poorer self-rated health in the Third US National Health and Nutrition Examination Survey

Antihypertensive treatment using an angiotensin receptor blocker and a thiazide diuretic improves patients’ quality of life: The Saga Challenge Antihypertensive Study (S-CATS)

Contact Info

Product

Resources

About